ClinicalTrials.gg
RecruitingNCT04511247FUTURE-BTKUpdated Jul 3, 2025

SirolimUs CoaTed Balloon for The TrEatment of Below The Knee Arterial Disease

An interventional study of MagicTouch PTA Sirolimus drug coated balloon and POBA balloon in Peripheral Artery Disease, Atherosclerosis and Arterial Disease of Legs, sponsored by Concept Medical Inc.. Recruiting at 20 sites in 3 countries. Open to participants aged 21 Years and older. Per ClinicalTrials.gov, last updated 2025-07-03.

Sponsored by Concept Medical Inc. · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Aug 2020; still recruiting 6 years 3 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
219
Allocation
Randomized
Ages
21 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 26 studies in Peripheral Arterial Disease with a site in Taiwan — 8 open to participants now, 8 under way, 3 of them phase 3. Peripheral Arterial Disease · Taiwan.

Planned enrollment
10th of 21
219 · median 212
Started
2020
with 4 others
No phase
11 of 26
5 open now
Registered
15th of 26
by date
Lead sponsor
2 of 26
Concept Medical Inc.

Among the 26 studies in Peripheral Arterial Disease with a site in Taiwan, this one is the 10th largest by planned enrollment of the 21 interventional ones that give a count, is one of 5 that started in 2020, is one of 11 with no phase, and was the 15th registered.

Peripheral Arterial Disease

1,378 studies on the registry are indexed under Peripheral Arterial Disease; 276 are open to participants now.

Browse Peripheral Arterial Disease studies →

Open to participants now

8 of the 26 studies in Peripheral Arterial Disease with a site in Taiwan are open now. Recruiting first, the newest first:

2 more — sign in →

All 8 open studies →

A study can be open while its sites in Taiwan have not opened yet or have stopped. Only those recruiting at a site in Taiwan →

Who these studies take

Of the 193 Peripheral Arterial Disease studies recruiting now, 139 (72%) set no upper age limit and 9 (5%) stop at 75 or younger; 13 take children under 18; 19 take healthy volunteers.

This study: 21 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 26 studies in Peripheral Arterial Disease with a site in Taiwan, or all of them as a file.
02

Study summary

This study aims to conduct a randomized, double blind, randomised controlled multicentre trial of sirolimus drug coated balloon versus standard percutaneous transluminal angioplasty for the treatment of below the knee arterial disease.

Read the detailed description

The burden of limb loss as a result of peripheral arterial disease (PAD) is high and this problem is set to worsen globally. Treatment of PAD primarily involves revascularisation of the limb. Angioplasty as a first line strategy of revascularization over surgical procedures has been adopted by most vascular centers. Local drug delivery using drug coated balloons (DCB) during angioplasty for PAD can successfully deliver effective local tissue concentrations of anti-proliferative drugs to the lesions in the artery involved in the PAD. This offers the potential for sustained anti-restenotic efficacy.

Randomized trials have shown superiority of Paclitaxel DCBs over just plain-balloon angioplasty for treatment of PAD, and DCB is now considered the standard of care. However, a recent meta-analyses which showed increased mortality at two years in patients treated with paclitaxel DCBs have called into question the safety of paclitaxel based DCBs.

Alternative drugs for DCBs are therefore urgently needed and sirolimus offers an attractive alternative. Compared to Paclitaxel, sirolimus is cytostatic in its mode of action with a high margin of safety. It has a high transfer rate to the vessel wall and has been shown to effectively inhibit neointimal hyperplasia in the porcine coronary model. In the coronary artery interventions, preliminary clinical studies using Sirolimus DCBs have also shown excellent procedural and 6 month patency.

03

Conditions studied

  • Peripheral Artery Disease
  • Atherosclerosis
  • Arterial Disease of Legs

Keywords

  • PAD
  • DCB
  • PTA
  • Sirolimus
04

Who can participate

Ages eligible
21 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age ≥ 21 years or minimum age
  2. Rutherford class 4 to 6 in the target limb

    Intraoperative Inclusion Criteria

  3. Single or sequential de novo or re-stenotic lesions (stenosis of > 50% or occlusions) from 2 to 20cm in the proximal 200mm of below the knee arteries. Lesion is considered as one lesion if there is maximum of 30mm gap between lesions at discretion of investigator. Below the knee arteries are tibioperoneal trunk, anterior tibial artery, posterior tibial artery and peroneal artery
  4. Inflow free from flow limiting lesions (\<50% stenosis) confirmed by duplex or angiography. Subjects with flow limiting inflow lesions (>50% stenosis) can be included if lesion had been treated successfully (\<30% residual stenosis) before or during the index procedure.
  5. Target vessel has angiographically documented run off to the foot after treatment (ie. without significant stenosis)

Exclusion criteria

Exclusion Criteria:

  1. Comorbid conditions limiting ≤ 1 year
  2. Subject is currently participating in another drug or device study that has not reached first primary endpoint yet
  3. Subject is pregnant or planning to become pregnant during the course of the study
  4. Heel gangrene
  5. Prior bypass surgery of target vessel
  6. Planned amputation of the target limb
  7. Previously implanted stent in the target lesion
  8. Vulnerable or protected adults
  9. Bleeding diathesis or another disorder such as gastrointestinal ulceration which restrict the use of clopidogrel or aspirin
  10. Known allergy to sirolimus

    Intraoperative Exclusion Criteria

  11. Failure to successfully cross the target lesion with a guide wire (successful crossing means tip of the guide wire distal to the target lesion in the absence of flow limiting dissections or perforations).
  12. Target vessel has lesions extending beyond the ankle joint
  13. Failure to obtain \<30% residual stenosis in a pre-existing lesion
  14. Lesions requiring retrograde access (SAFARI)
  15. Highly calcified lesions (Contiguous calcification on both sides of the lesion)
  16. Use of DCBs, drug eluting stent, specialty balloons or artherectomy devices during the index procedure. (Non-compliant balloons are not considered specialty balloons)
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
219 participants (estimated)

Study arms

  • Experimental
    MagicTouch PTA sirolimus drug coated balloon (DCB)

    MagicTouch PTA sirolimus drug coated balloon (DCB) in addition to standard balloon angioplasty

    Device: MagicTouch PTA Sirolimus drug coated balloon

  • Active comparator
    Placebo balloon angioplasty

    Placebo balloon angioplasty in addition to standard balloon angioplasty (PTA)

    Device: POBA balloon

Interventions

  • DeviceMagicTouch PTA Sirolimus drug coated balloon

    For participants randomised to MagicTouch PTA sirolimus DCB, following successful plain balloon angioplasty of the arterial lesion (defined as \<30% residual stenosis after treatment at rated burst pressure of the angioplasty balloon), MagicTouch sirolimus coated balloon will be applied at the lesion after appropriate sizing using the diameter of the plain balloon angioplasty.

  • DevicePOBA balloon

    For participants randomised to the standard balloon angioplasty group, a placebo standard balloon which is identical to the SCB will also be applied at the lesion after appropriate sizing using the diameter of the plain balloon angioplasty

06

What researchers measure

Primary outcomes

  1. Primary patency at 6 months

    Primary patency rate at 6 months defined as proportion of subjects with duplex ultrasonography-derived peak systolic velocity ratio of ≤ 2.4 (in absence of target lesion revascularisation)

    Time frame: 6 months

Secondary outcomes

  1. Device and procedure related deaths

    Proportion of device and procedure related deaths

    Time frame: 1,6,12 and 24 Months

  2. All-cause death

    Proportion of subjects died by any-cause

    Time frame: 1,6,12 and 24 Months

  3. Major target limb amputation

    Proportion of subjects with major target limb amputation

    Time frame: 6,12 and 24 Months

  4. Target vessel thrombosis

    Proportion of subjects with target vessel thrombosis

    Time frame: From day 0 to day 14

  5. Proportion of subjects who experienced either death at 6 month or major target limb amputation at 6 month or target vessel thrombosis within 14 days.

    Proportion of subjects who experienced either death at 6 month or major target limb amputation at 6 month or target vessel thrombosis within 14 days.

    Time frame: Day 0 to day 14, 6 Months

  6. Occurrence of adverse events (AEs), serious AEs and AEs related to device and procedure

    Occurrence of adverse events (AEs), serious AEs and AEs related to device and Occurrence of adverse events (AEs), serious AEs and AEs related to device and procedure

    Time frame: From Day 0 to 24 Months Follow-up

  7. Procedural Success

    Proportion of subjects with procedural success during hospital stay

    Time frame: From Day 1 to discharge up to maximum of 30 days

  8. Proportion of subjects who are free from clinically-driven Target Lesion Revascularization (TLR)

    Proportion of subjects who are free from clinically-driven TLR

    Time frame: 6,12 and 24 Months

  9. Proportion of subjects who are free from clinically-driven Target Vessel Revascularization (TVR)

    Proportion of subjects who are free from clinically-driven Target Vessel Revascularization (TVR)

    Time frame: 6,12 and 24 Months

  10. Primary patency

    Primary patency rate at 12 and 24 months

    Time frame: 12 and 24 Months

  11. Restenosis

    Proportion of subjects with restenosis

    Time frame: 6, 12 and 24 Months

  12. Subjects who are free from MAE

    Proportion of subjects who are free from MAE

    Time frame: 6 Months

  13. Amputation-free survival

    Amputation-free survival

    Time frame: 6, 12 and 24 Months

  14. Clinical Success

    Proportion of subjects with clinical Success at 6, 12 and 24 months, Clinical success is defined as Improvement in Rutherford classification compared to the pre-procedure Rutherford classification

    Time frame: 6, 12 and 24 Months

  15. Device success

    Proportion of subjects with device success at day 1

    Time frame: Day 1

  16. Technical success

    Proportion of subjects with technical success at day 1

    Time frame: Day 1

  17. Wound assessment (if any)

    Wound assessment (if any)

    Time frame: 1, 6, 12, 24 Months

  18. Toe Pressure or ABPI assessment

    Toe Pressure or ABPI assessment

    Time frame: 6, 12, 24 Months

Other outcomes

  1. Health-related quality of life

    Mean change from baseline in EuroQol-5Dimensions (EQ-5D) health-related quality of life questionnaire score at 12 and 24 months. The score ranges from 0 to 1, and a higher score means a better outcome

    Time frame: 12 and 24 months

  2. Walking impairment

    Mean change from baseline in walking impairment questionnaire score at 12 and 24 months. The score ranges from 0% to 100% and a higher score means a better outcome

    Time frame: 12 and 24 months

07

Study locations

17 of 20 sites recruiting
08

References and documents

Publications

  • Giacoppo D, Cassese S, Harada Y, Colleran R, Michel J, Fusaro M, Kastrati A, Byrne RA. Drug-Coated Balloon Versus Plain Balloon Angioplasty for the Treatment of Femoropopliteal Artery Disease: An Updated Systematic Review and Meta-Analysis of Randomized Clinical Trials. JACC Cardiovasc Interv. 2016 Aug 22;9(16):1731-42. doi: 10.1016/j.jcin.2016.06.008. PubMed 27539695 ↗
  • Clever YP, Peters D, Calisse J, Bettink S, Berg MC, Sperling C, Stoever M, Cremers B, Kelsch B, Bohm M, Speck U, Scheller B. Novel Sirolimus-Coated Balloon Catheter: In Vivo Evaluation in a Porcine Coronary Model. Circ Cardiovasc Interv. 2016 Apr;9(4):e003543. doi: 10.1161/CIRCINTERVENTIONS.115.003543. PubMed 27069105 ↗
  • Verheye S, Vrolix M, Kumsars I, Erglis A, Sondore D, Agostoni P, Cornelis K, Janssens L, Maeng M, Slagboom T, Amoroso G, Jensen LO, Granada JF, Stella P. The SABRE Trial (Sirolimus Angioplasty Balloon for Coronary In-Stent Restenosis): Angiographic Results and 1-Year Clinical Outcomes. JACC Cardiovasc Interv. 2017 Oct 23;10(20):2029-2037. doi: 10.1016/j.jcin.2017.06.021. Epub 2017 Sep 27. PubMed 28964764 ↗
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Aug 2020 (actual). Primary completion is estimated for Dec 2026, 76 months after the start.

Of 125 industry-sponsored interventional studies with no phase under Peripheral Arterial Disease, half reached primary completion within 28 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 45. This study's planned 76 months is above that.

Counting every sponsor, half of 386 studies reached it within 31 months; a quarter within 17 and three quarters within 55.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 5, 2020
First posted
Aug 13, 2020
StartActual
Aug 15, 2020
Primary completionEst.
Dec 2026
CompletionEst.
Dec 2027
Last update
Jul 3, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 3, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04511247
Lead sponsor
Concept Medical Inc.
Responsible party
Sponsor
First posted
Aug 13, 2020
Start date
Aug 15, 2020
Primary completion
Dec 2026 (estimated)
Completion
Dec 2027 (estimated)
Last update
Jul 3, 2025

Study contacts

Edward Choke
Contact
tcchoke@hotmail.com
+65 69302164
Edward Choke
principal investigator · Sengkang General Hospital

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion